The life sciences industry, including medicinal products and medical device, is one of the UK's leading manufacturing sectors. It is also one of the most highly regulated sectors; the current UK legal framework governing medicines and medical devices derives largely from EU legislation.
As a result, Brexit could give rise to questions concerning the on-going validity of marketing authorisations and CE marks, result in disruption to supply of these products to patients and physicians, give rise to additional testing obligations for UK products being placed on the EU market, new export charges, and uncertainty regarding the future regulatory regime to be applied to medicinal products and medical devices.
We have been leading analysis of Brexit since before the referendum was promised. We have been collaborating with our clients and other experts to provide a holistic view of the related risks and opportunities. We are ready to help you to best address the evolving potential consequences of Brexit by delivering sound legal analysis, global perspective and active engagement with policy makers.